Immune checkpoint inhibitors have become a target for pharmacological research in lung cancer. Immune-related adverse events (irAEs) such as pneumonitis, colitis, hepatitis and endocrinopathies have been well characterized in immune checkpoint inhibitors, but coronary toxicities, like acute coronary syndrome, are poorly described. Herein, we report a possible acute coronary syndrome as immune-related adverse event in a lung cancer patient.
TopalianSLHodiFSBrahmerJR, et al.Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med2012; 366: 2443–2454.
2.
NishinoMShollLMHodiFS, et al.Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med2015; 373: 288–290.
3.
JohnsonDBBalkoJMComptonML, et al.Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med2016; 375: 1749–1755.
4.
TomitaYSuetaDKakiuchiY, et al.Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint antibody. Ann Oncol2017; 28: 2893–2895.
5.
FerreiraMPichonECarmierD, et al.Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a case report and review of the literature and international registries. Target Oncol2018; 13: 509–515.
6.
FoksACKuiperJ. Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis. Br J Pharmacol2017; 174: 3940–3955.
7.
ChenJHPezhouhMKLauwersGY, et al.Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies. Am J Surg Pathol2017; 41: 643–654.
8.
Freeman-KellerMKimYCroninH, et al.Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res2016; 22: 886–894.
9.
NaranjoCABustoUSellersEM, et al.A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981; 30: 239–245.
